Drug Trial Radar · NCT02486718
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,280
Actual
Start
Oct 31, 2015
Primary completion
Jan 26, 2024
Study completion Aug 26, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.
Conditions
- Non-Small Cell Lung Cancer
Interventions
AtezolizumabDrug
Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
CisplatinDrug
Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.
VinorelbineDrug
Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
DocetaxelDrug
Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
GemcitabineDrug
Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
PemetrexedDrug
Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-Free Survival (DFS) in Intent-to-treat (ITT) PopulationTime frame: Up to 95 months
- DFS in All Randomized Stage II-IIIA PopulationTime frame: Up to 95 months
- DFS in the Programmed Death-ligand 1 (PD-L1) SP263 ≥ 1% Tumor Cell (TC) Subpopulation Within the Stage II-IIIA PopulationTime frame: Up to 95 months
Locations
216 sites in 22 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Fayetteville, Arkansas
California Cancer Associates for Research & Excellence, Inc.
Encinitas, California
Compassionate Cancer Care Medical Group, Inc
Fountain Valley, California
University of California Los Angeles
Los Angeles, California
Southern California Permanente Medical Group Bellflower
Los Angeles, California
Stanford University
Stanford, California
Kaiser Permanente
Vallejo, California
Kaiser Permanente - Walnut Creek
Walnut Creek, California
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut
Lynn Cancer Institute - West
Boca Raton, Florida
University of Miami School of Medicine - Sylvester at Deerfield
Deerfield Beach, Florida
Holy Cross Hospital Inc
Fort Lauderdale, Florida
Florida Cancer Specialists-Broadway, Fort Myers
Fort Myers, Florida
SCRI Florida Cancer Specialists North
St. Petersburg, Florida
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
Marietta, Georgia
Lewis Hall Singletary Oncology Center
Thomasville, Georgia
Rush University Medical Center
Chicago, Illinois
University of Illinois at Chicago
Chicago, Illinois
Illinois Cancer Care
Peoria, Illinois
Southern Illinois University, Simmons Cancer Institute
Springfield, Illinois
Norton Cancer Institute
Louisville, Kentucky
St. Luke's Cancer Institute
Kansas City, Missouri
Comprehensive Cancer Centers of Nevada
Henderson, Nevada
Hematology Oncology Associates of Northern New Jersey
Florham Park, New Jersey
Saint Barnabas Medical Center
Livingston, New Jersey
Valley Hospital
Paramus, New Jersey
Overlook Medical Center
Summit, New Jersey
Clinical Research Alliance
Lake Success, New York
Weill Cornell Medical College
New York, New York
Presbyterian Hospital
Charlotte, North Carolina
University of Cincinnati
Cincinnati, Ohio
Oncology Hematology Care - SCRI
Cincinnati, Ohio
Oregon Health and Science University
Portland, Oregon
Pinnacle Health
Harrisburg, Pennsylvania
AHN Cancer Institute ? Allegheny General Hospital
Pittsburgh, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Sarah Cannon Research Institute / Tennessee Oncology
Chattanooga, Tennessee
University Oncology Associates
Chattanooga, Tennessee
Sarah Cannon Cancer Center
Nashville, Tennessee
Houston Methodist Cancer Center
Houston, Texas
Showing 40 of 216 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.